Infection by SARS-CoV-2 with alternate frequencies of mRNA vaccine boosting

被引:13
|
作者
Townsend, Jeffrey P. [1 ,2 ,3 ,4 ,6 ]
Hassler, Hayley B. [1 ]
Dornburg, Alex [5 ]
机构
[1] Yale Sch Publ Hlth, Dept Biostat, New Haven, CT USA
[2] Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT USA
[3] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT USA
[4] Yale Univ, Program Microbiol, New Haven, CT USA
[5] Univ N Carolina, Dept Bioinformat & Genom, Charlotte, NC USA
[6] Yale Sch Publ Hlth, Dept Biostat, 135 Coll St, New Haven, CT 06510 USA
基金
美国国家科学基金会;
关键词
BNT162b2; mRNA-1273; mRNA vaccines; SARS-CoV-2 variant evolution; updated COVID-19 vaccine; vaccination schedule; ANTIBODY-RESPONSES; DURATION; COVID-19;
D O I
10.1002/jmv.28461
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
One of the most consequential unknowns of the COVID-19 pandemic is the frequency at which vaccine boosting provides sufficient protection from infection. We quantified the statistical likelihood of breakthrough infections over time following different boosting schedules with messenger RNA (mRNA)-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech). We integrated anti-Spike IgG antibody optical densities with profiles of the waning of antibodies and corresponding probabilities of infection associated with coronavirus endemic transmission. Projecting antibody levels over time given boosting every 6 months, 1, 1.5, 2, or 3 years yielded respective probabilities of fending off infection over a 6-year span of >93%, 75%, 55%, 40%, and 24% (mRNA-1273) and >89%, 69%, 49%, 36%, and 23% (BNT162b2). Delaying the administration of updated boosters has bleak repercussions. It increases the probability of individual infection by SARS-CoV-2, and correspondingly, ongoing disease spread, prevalence, morbidity, hospitalization, and mortality. Instituting regular, population-wide booster vaccination updated to predominant variants has the potential to substantially forestall-and with global, widespread uptake, eliminate-COVID-19.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] INADEQUATE SARS-COV-2 ANTIBODY RESPONSE TO MRNA SARS-COV-2 VACCINE IN ADOLESCENT KIDNEY TRANSPLANT RECIPIENTS
    Loop, L.
    Crane, C.
    Anterasian, C.
    Geng, B.
    Ingulli, E.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (05) : S7 - S8
  • [22] Fluctuations of SARS-CoV-2 Antibody Concentrations with Age in Vaccine Naive Population with SARS-CoV-2 Infection
    Akinyemi, A.
    Wantuch, A.
    Errath, A.
    Manjee, K.
    Benirschke, R. C.
    Lee, H.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2022, 158 (SUPP 1) : S138 - S139
  • [23] The Effect of Vaccine Type and SARS-CoV-2 Lineage on Commercial SARS-CoV-2 Serologic and Pseudotype Neutralization Assays in mRNA Vaccine Recipients
    Tolan, Nicole, V
    Sherman, Amy C.
    Zhou, Guohai
    Nabel, Katherine G.
    Desjardins, Michael
    Melanson, Stacy
    Kanjilal, Sanjat
    Moheed, Serina
    Kupelian, John
    Kaufman, Richard M.
    Ryan, Edward T.
    LaRocque, Regina C.
    Branda, John A.
    Dighe, Anand S.
    Abraham, Jonathan
    Baden, Lindsey R.
    Charles, Richelle C.
    Turbett, Sarah E.
    MICROBIOLOGY SPECTRUM, 2022, 10 (02):
  • [24] Design and Preclinical Evaluation of a Universal SARS-CoV-2 mRNA Vaccine
    Langston, Laura Katherine
    Xu, Renhuan
    Zhu, Huabin
    Qin, Jane
    Jeon, Ju
    Xu, Jiangsheng
    Mou, Stephanie
    JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
  • [25] Skin reactions to mRNA-1273 SARS-CoV-2 vaccine
    Wang, Ruei-Lin
    Huang, Li-Yen
    Yang, Chung-Chi
    Hsieh, Chung-Yueh
    Wu, Kuo-An
    Chan, Jenq-Shyong
    Wu, Kun-Lin
    Shyu, Hann-Yen
    Kao, Yung-Hsi
    Shang, Shih-Ta
    Hsiao, Po-Jen
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2022, 115 (12) : 878 - 878
  • [26] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
    Baden, Lindsey R.
    El Sahly, Hana M.
    Essink, Brandon
    Kotloff, Karen
    Frey, Sharon
    Novak, Rick
    Diemert, David
    Spector, Stephen A.
    Rouphael, Nadine
    Creech, C. Buddy
    McGettigan, John
    Khetan, Shishir
    Segall, Nathan
    Solis, Joel
    Brosz, Adam
    Fierro, Carlos
    Schwartz, Howard
    Neuzil, Kathleen
    Corey, Larry
    Gilbert, Peter
    Janes, Holly
    Follmann, Dean
    Marovich, Mary
    Mascola, John
    Polakowski, Laura
    Ledgerwood, Julie
    Graham, Barney S.
    Bennett, Hamilton
    Pajon, Rolando
    Knightly, Conor
    Leav, Brett
    Deng, Weiping
    Zhou, Honghong
    Han, Shu
    Ivarsson, Melanie
    Miller, Jacqueline
    Zaks, Tal
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05): : 403 - 416
  • [27] SARS-CoV-2: Efficacy and Safety of the mRNA-1273 Vaccine
    Metzger, Leandra
    PNEUMOLOGIE, 2022, 76 (03): : 154 - 154
  • [28] Ramsay Hunt syndrome following mRNA SARS-COV-2 vaccine
    Rodriguez-Martin, Minerva
    Corriols-Noval, Patricia
    Lopez-Simon, Eugenia
    Morales-Angulo, Carmelo
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2022, 40 (01): : 47 - 48
  • [29] SARS-CoV-2 mRNA vaccine: Sometimes life needs a boost
    Lo, Carson Ka-Lok
    Kumar, Deepali
    TRANSPLANT INFECTIOUS DISEASE, 2023,
  • [30] Serological response to a single dose of a SARS-CoV-2 mRNA vaccine
    Ramos, Angelica
    Cardoso, Maria Joao
    Norton, Pedro
    Sarmento, Antonio
    Guimaraes, Joao Tiago
    JOURNAL OF VIROLOGICAL METHODS, 2021, 296